Analysts expect Hologic, Inc. (NASDAQ:HOLX) to announce earnings per share (EPS) of $0.59 for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Hologic’s earnings, with estimates ranging from $0.57 to $0.60. Hologic posted earnings per share of $0.50 during the same quarter last year, which would indicate a positive year over year growth rate of 18%. The firm is expected to report its next quarterly earnings report after the market closes on Wednesday, November 7th.
On average, analysts expect that Hologic will report full year earnings of $2.24 per share for the current fiscal year, with EPS estimates ranging from $2.22 to $2.25. For the next fiscal year, analysts forecast that the firm will report earnings of $2.41 per share, with EPS estimates ranging from $2.34 to $2.57. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Hologic.
A number of equities analysts have recently weighed in on HOLX shares. ValuEngine raised Hologic from a “sell” rating to a “hold” rating in a research report on Wednesday, July 11th. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a research report on Wednesday, August 1st. Needham & Company LLC upped their target price on Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Deutsche Bank upped their target price on Hologic from $42.00 to $45.00 and gave the stock a “hold” rating in a research report on Wednesday, August 1st. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $50.00 price target on shares of Hologic in a research report on Wednesday, August 1st. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $44.47.
Shares of NASDAQ:HOLX traded up $0.21 during trading on Thursday, reaching $40.20. 123,566 shares of the stock were exchanged, compared to its average volume of 1,989,980. The company has a quick ratio of 0.99, a current ratio of 1.29 and a debt-to-equity ratio of 1.12. Hologic has a 1-year low of $35.10 and a 1-year high of $45.09. The firm has a market capitalization of $10.92 billion, a price-to-earnings ratio of 19.88, a PEG ratio of 1.83 and a beta of 0.65.
In other news, Director Sally Crawford sold 13,257 shares of the firm’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $39.54, for a total transaction of $524,181.78. Following the completion of the sale, the director now directly owns 167,701 shares of the company’s stock, valued at approximately $6,630,897.54. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Benjamin Jordan Cohn sold 3,437 shares of the firm’s stock in a transaction on Wednesday, September 19th. The shares were sold at an average price of $41.50, for a total value of $142,635.50. Following the sale, the insider now directly owns 16,520 shares of the company’s stock, valued at $685,580. The disclosure for this sale can be found here. Insiders sold a total of 47,661 shares of company stock valued at $1,927,174 over the last three months. 0.88% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in HOLX. Jane Street Group LLC increased its position in shares of Hologic by 30.3% during the 1st quarter. Jane Street Group LLC now owns 6,904 shares of the medical equipment provider’s stock valued at $258,000 after purchasing an additional 1,607 shares during the last quarter. CIBC World Markets Inc. bought a new position in shares of Hologic during the 1st quarter worth $359,000. Principal Financial Group Inc. grew its stake in shares of Hologic by 0.5% during the 1st quarter. Principal Financial Group Inc. now owns 406,319 shares of the medical equipment provider’s stock worth $15,180,000 after acquiring an additional 2,131 shares during the period. DnB Asset Management AS bought a new position in shares of Hologic during the 2nd quarter worth $1,248,000. Finally, Curbstone Financial Management Corp bought a new position in shares of Hologic during the 2nd quarter worth $847,000. 98.74% of the stock is owned by hedge funds and other institutional investors.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: Stop Order
Get a free copy of the Zacks research report on Hologic (HOLX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.